Gene Therapy for Cardiovascular Disorders - Applications of Biotechnology in Cardiovascular Therapeutics - page 255

Companies Involved in Gene Therapy of Cardiovascular
Disorders

Companies involved in gene therapy of cardiovascular disorders are shown in
Table 8.4 .

Table 8.4 Companies involved in gene therapy of cardiovascular diseases

Company Technology/product/applications Stage

AnGes MG Inc Hepatocyte growth factor for angiogenesis/

PVD and CAD

Filed in
Japan

Ark Therapeutics Trinam ™ : consists of a local delivery device

and a gene-based medicine to prevent
thrombosis of veins and arteries after

Phase II/III

Berlex (now part of Bayer
Healthcare)

Ad5FGF-4 angiogenic gene therapy product
for the treatment of patients with stable
exertional angina due to CAD

Phase IIB/III
halted

BioCardia Inc Catheter for percutaneous intramyocardial

gene delivery

Research

Biosense Webster/
Sanofi-Aventis

The NOGA system is catheter-based system
for intramyocardial navigation to deliver
angiogenesis gene therapy (FGF1) to treat
cardiovascular disease

Phase II

Cardium GENERX (Ad5-FGF4) for gene therapy of

patients with angina due to CAD

Phase II/III
on going

Celladon Corporation/
Targeted Genetics Corp

MYDICAR ® targeting SERCA2a: AAV-based
gene therapy for CHF

Phase I/II

Cordis Corporation
(Johnson & Johnson)

NOGA ® Cardiac Navigation System for
delivery of cardiac cell and gene therapies

Marketed

Expression Genetics Water-soluble lipopolymer is a local or systemic

gene therapy delivery system to prevent and
treat cardiovascular diseases

Preclinical

Genzyme GeneGraft, based on engineered HIF-1a gene,

to promote angiogenesis in PAD and IHD

Phase I

The proprietary gene therapy BARKct prevents
congestive heart failure and reverses prior
damage to heart tissue

Preclinical

NanoCor Therapeutics Targeted noninvasive delivery of a gene,

Carfostin ® , with BNP ™ (Biological
NanoParticle) and rAAV for treatment
of CHF

Preclinical

Sanofi-Aventis Temusi ® (NV1FGF; riferminogen pecaplasmid):

nonviral plasmid-based local IM gene-
delivery for FGF-1 angiogenic therapy for
critical limb ischemia

Phase III
failed

ViroMed Co Ltd/
Takara Bio

Gene-based drug, VMDA3601 for patients
suffering from critical limb ischemia and IHD

Phase I

Abbreviations : CAD coronary artery disease, PAD peripheral arterial disease, IHD ischemic heart
disease, CHF congestive heart failure